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Background: αVβ3, αVβ5 and α5β1 integrins are known to be involved in
carcinogenesis and are overexpressed in many types of tumours compared to
healthy tissues; thereby they have been selected as promising therapeutic targets.
Positron emission tomography (PET) is providing a unique non-invasive screening assay
to discriminate which patient is more prone to benefit from antiangiogenic therapies,
and extensive research has been carried out to develop a clinical radiopharmaceutical
that binds specifically to integrin receptors. We recently reported the synthesis of a
new 18F-labelled RGD peptide prepared by 2-cyanobenzothiazole (CBT)/1,2-
aminothiol conjugation. This study aims at characterising the preclinical biologic
properties of this new tumour-targeting ligand, named [18F]FPyPEGCBT-c(RGDfK).
The in vitro binding properties of [18F]FPyPEGCBT-c(RGDfK) were analysed by standard
binding assay in U-87 MG and SKOV-3 cancer models and its selectivity towards
integrins by siRNA depletions. Its preclinical potential was studied in mice bearing
subcutaneous tumours by ex vivo biodistribution studies and in vivo microPET/CT
imaging.
Results: In vitro, FPyPEGCBT-c(RGDfK) efficiently bound RGD-recognising integrins
as compared to a control c(RGDfV) peptide (IC50 = 30.8 × 10
−7 M vs. 6.0 × 10−7 M).
[18F]FPyPEGCBT-c(RGDfK) cell uptake was mediated by an active transport through
binding to αV, β3 and β5 but not to β1 subunits. In vivo, this new tracer demonstrated
specific tumour uptake with %ID/g of 2.9 and 2.4 in U-87 MG and SKOV-3 tumours 1 h
post injection. Tumour-to-muscle ratios of 4 were obtained 1 h after intravenous
administration of the tracer allowing good visualisation of the tumours. However,
unfavourable background accumulation and high hepatobiliary excretion were
observed.
Conclusion: [18F]FPyPEGCBT-c(RGDfK) specifically detects tumours expressing
RGD-recognising integrin receptors in preclinical studies. Further optimisation of this
radioligand may yield candidates with improved imaging properties and would warrant
the further use of this efficient labelling technique for alternative targeting vectors.
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Positron Emission Tomography (PET) is a sensitive nuclear imaging method to diagnose
and stage cancers, particularly when images are co-registered with Computed Tomography
(CT) or Magnetic Resonance Imaging (MRI) (Gambhir 2002; Yankeelov et al. 2014).
Diagnosis of patients suspected of having cancer is commonly investigated by PET/
CT scans with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) (Fletcher et al. 2008). Fur-
thermore, 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT), a positron emitting thymidine
derivative, is often used to monitor cancer response towards chemotherapy (Tehrani
and Shields 2013). Both small molecule tracers have shown diagnostic potential and
efficacy in predicting tumour response to treatment, but only after initiation of the
therapeutic regimen. Moreover, their organ uptakes are mediated by high tissue
metabolism and proliferation, respectively, which impairs their specificity towards
tumour tissue. Thus, identification of PET tracers targeting specific proteins which
are solely overexpressed in cancer tissues (e.g. cell membrane receptors) (Eberle and
Mild 2009) could greatly facilitate the deployment of personalised medicine strategies
(Doroshow and Kummar 2014).
Several cell membrane receptors are known to be highly expressed in cancer tissues.
Among them, integrin receptors are of particular interest since they are implicated in
angiogenesis, tumour growth and metastasis. They are also overexpressed in endothelial
cells of the tumor vasculature where they promote cell migration (Avraamides et al.
2008; Desgrosellier and Cheresh 2010). The Arginine-Glycine-Aspartic acid (RGD)-
recognising αVβ3, αVβ5 and α5β1 heterodimeric transmembrane receptors have been
selected as the most attractive targets among the integrin receptors for antiangiogenic
therapy and diagnosis, as recently and exhaustively reviewed by Danhier et al. (Danhier
et al. 2012). RGD-recognising integrins are involved in other physiopathological processes
implicating angiogenesis and/or inflammation (e.g. atherosclerosis), which further
highlights the importance of these targets for the development of non-invasive
imaging probes (Antonov et al. 2004).
A number of RGD-derived peptide tracers for integrin-based PET imaging have
already been described. Among them, those labelled with 64Cu and 68Ga radionuclides
have shown promising preclinical results (Dumont et al. 2011; Pohle et al. 2012).
However, to date only [68Ga]NOTA-c(RGDyK) has been evaluated clinically (Jeong
et al. 2008; Kim et al. 2012). More 18F-labelled RGD peptides have reached clinical
trials (Cai and Conti 2013; Haubner et al. 2014a), in large part due to the attractive
nuclear properties of 18F and its pervasive availability at most PET centres. Among
the most potent RGD peptides is the glycosylated cyclic RGD analogue, [18F]galacto-
c(RGDfK), which has shown specific binding to integrin-expressing tumours both in
preclinical and clinical settings (Haubner et al. 2001; Haubner et al. 2005; Beer et al.
2006; Haubner et al. 2004). An attempt to optimise the radiosynthesis and in vivo
biodistribution of such sugar-tethered RGD radiopeptides was recently investigated,
and efforts yielded a potent maltose-derived tracer (Maschauer et al. 2014). In
parallel, in vivo behaviours of RGD tracers bearing amphiphilic polyethylene glycol
(PEG) chains (Harris and Chess 2003), such as the PEGylated [18F]Fluciclatide
analogue ([18F]-AH111585), were also studied (Tomasi et al. 2011; Kenny et al. 2008;
Battle et al. 2011). Another approach is to use petides containing two or more
integrin-recognising units to increase the affinity and the bioavailability. Dimers of
Fig. 1 Synthesis of [18,19F]FPyPEGCBT-c(RGDfK)
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nitrophenyl 2-[18F]fluoropropionate ([18F]NFP) to yield [18F]FRGD2 and [18F]FPPRGD2,
respectively (Chen et al. 2004a; Zhang et al. 2006; Wu et al. 2007a; Choyke 2011; Mittra
et al. 2011; Liu et al. 2010). They are both good candidate tracers to image angiogenesis
and are currently under clinical investigations.
In light of these encouraging results, we recently synthesised a new c(RGDfK)-based
PET tracer via conjugation of a 18F-labelled PEGylated cyanobenzothiazole prosthetic
group ([18F]FPyPEGCBT) with a c(RGDfK) peptide containing a cysteine residue at the
terminus of the PEG chain (Fig. 1) (Inkster et al. 2015). This bioconjugation reaction
was chosen since it adheres to all “click chemistry” criteria and it has previously
demonstrated great potential to label sensitive biomolecules (Kolb et al. 2001; Jeon
et al. 2012; Kettenbach et al. 2014). We report herein the preclinical biological
characteristics of [18F]FPyPEGCBT-c(RGDfK). In vitro binding affinity and selectivity of
[18F]FPyPEGCBT-c(RGDfK) towards αVβ3, αVβ5 and α5β1 integrins were assessed in
U-87 MG and SKOV-3 relevant glioblastoma and ovarian cancer cell lines. Its poten-
tial as a molecular imaging agent was further studied in mice bearing the same
tumour models by ex vivo biodistribution assays and in vivo microPET/CT imaging.Methods
Chemicals
All reagents were obtained from Sigma-Aldrich (Buchs, Switzerland) unless specified.
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[18F]FPyPEGCBT-c(RGDfK) was prepared via the reported method (Inkster et al.
2015). In summary, 18F prosthetic group [18F]FPyPEGCBT was prepared by way of
nucleophilic aromatic [18F]fluorination of its 2-trimethylammonium pyridine precursor
and partially purified by solid-phase extraction on molecularly imprinted polymer sorbent
(AffiniMIP®). [18F]FPyPEGCBT was then coupled to cysteine-modified c(RGDfK) in DMF
over 30 minutes at 43 °C. [18F]FPyPEGCBT-c(RGDfK) was purified by High Performance
Liquid Chromatography (HPLC) and formulated in 10 % EtOH in isotonic saline for
preclinical use. The entire synthesis was completed on a single automated synthesis
unit (GE Healthcare, Ecublens, Switzerland) over 124–132 min.Cell lines
The U-87 MG glioblastoma and SKOV-3 ovarian cancer cell lines (ECACC, Salisbury,
UK) were cultured at 37 °C and 5 % CO2 in Dulbecco’s Modified Eagle Medium
(DMEM; Life Technologies, Zug, Switzerland) supplemented with 10 % (v/v) fetal calf
serum (Life Technologies).siRNA transfection
siRNAs targeting human αV, β1, β3 or β5 integrin subunits were synthesised by MWG
(Ebersberg, Germany). siRNA sequences used were: for αV, sense 5′-UCCAUUCAU
GUACUUUUCC-3′; β1, sense 5′-AUGUAACCAACCGUAGCA-3′; β3, sense 5′-CAA
GCCUGUGUCACCAUAC-3′; β5, sense 5′-GCUCGCAGGUCUCAACAUA-3′. An
siRNA targeting luciferase was used as a non-specific control, sense 5′-CGUACGCG
GAAUACUUCGA-3′. 48 h prior to an experiment, U-87 MG (4 × 104 cells per well)
and SKOV-3 (1 × 104 cells per well) cells were reverse transfected in 96-well plates
with a final concentration of 50 nM of indicated siRNAs using RNAiMAX (Life
Technologies) according to the manufacturer’s protocol.Immunoblotting
Protein extracts were prepared in a RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1 %
SDS, 0.5 % Na deoxycholate, 1 % Igepal CA630, 2 mM EDTA, 50 mM NaF, pH 8)
containing a cocktail of protease inhibitors (Roche, Rotkreuz, Switzerland) and titrated
using the DC Protein Assay (Biorad, Cressier, Switzerland). Five to 10 μg of protein
extracts were separated by SDS-PAGE and transferred onto nitrocellulose membranes
(Amersham, GE Healthcare, Glattbrugg, Switzerland). Membranes were blocked for 1 h
at room temperature, incubated overnight at 4 °C with primary antibodies, incubated
for 1 h with secondary antibodies, developed using standard ECL protocol and analysed
using a Chemidoc MP (Biorad). The primary antibodies raised against αV (611012),
β1 (610467) and β3 (611140) integrins were from BD (Allschwil, Switzerland), against β5
integrin (3629S) from Cell Signalling (Berverly, MA, USA) and Actin (A2066) from
Sigma-Aldrich. HRP-conjugated secondary antibodies were obtained from Biorad.Cell binding assay
In vitro integrin-binding of FPyPEGCBT-c(RGDfK) was evaluated using a standard
displacement assay of [125I]echistatin. U-87 MG and SKOV-3 cells were seeded in
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SKOV-3, 3 × 104 cells per well). On the day of the experiment, the cells were
washed twice with binding buffer (20 mM Tris pH 7.4, 150 mM NaCl, 2 mM
CaCl2, 1 mM MgCl2, 1 mM MnCl2, 0.1 % BSA), then co-incubated for 1 h at 37 °C in
binding buffer with 370 Bq/well [125I]echistatin (Perkin Elmer, Schwerzenbach,
Switzerland) and a concentration range (10−9 to 10−4 M) of FPyPEGCBT-c(RGDfK) or
c(RGDfV) (PeptaNova, Sandhausen, Germany) as a reference peptide. Cells were then
washed three times with binding buffer and lysed in 1 M NaOH. The cell-associated
radioactivity was measured in a Wizard2 2470 γ-counter (Perkin Elmer). The IC50
(Inhibitory Concentration of 50 %) values were calculated by fitting the data by non-
linear regression using GraphPad Prism (GraphPad software, La Jolla, CA, USA).Cell uptake assay
U-87 MG (6 × 104 cells per well) and SKOV-3 (3 × 104 cells per well) cells were seeded in
96-well plates 24 h prior to the experiment. On the day of the experiment, cells were
washed twice with binding buffer (20 mM Tris pH 7.4, 150 mM NaCl, 2 mM CaCl2,
1 mM MgCl2, 1 mM MnCl2, 0.1 % BSA) then incubated for 15 to 120 min with 100 kBq/
mL [18F]FPyPEGCBT-c(RGDfK) in binding buffer at 37 or 4 °C. Cells were also co-treated
with 10−4 M c(RGDfV) for 1 h. [18F]FPyPEGCBT-c(RGDfK) uptake in cells with siRNA-
mediated depletions of specific integrin subunits was also assessed. After indicated uptake
times, cells were washed three times with binding buffer and lysed in 1 M NaOH. The
cell-associated radioactivity was measured in a Wizard2 2470 γ-counter (Perkin Elmer).Animal models
All animal experiments were performed in compliance with the current Swiss animal
protecting laws and protocols of the local authorities (approval G36/3528). Six to eight
weeks old female BALB/c nude mice (Harlan, Horst, The Netherlands) were injected
subcutaneously into the right flank with 1 × 106 U-87 MG or SKOV-3 cancer cells in
200 μL of a matrix containing 30 % of DMEM and 70 % of HyStem-C hydrogel (ESI
BIO, Alameda, CA, USA). After two weeks, when tumour volumes were approximately
500 mm3, the animals were used for microPET/CT and/or biodistribution studies.Biodistribution study
Mice were anesthetised with 2 % isoflurane and were injected retro-orbitally in the
venous sinus with 3–5 MBq of [18F]FPyPEGCBT-c(RGDfK). Mice were then left awake
during the uptake times of 30, 60 or 120 min. For the blocking experiments, mice were
injected intravenously with 20 mg/kg of c(RGDfV) 5 min prior to the tracer. Mice were
then anesthetised, blood was collected by intracardiac puncture and the animals were
sacrificed. Indicated organs and tumours were collected, weighed, and the radioactivity
quantified in a Wizard2 2470 γ-counter. Data were expressed as percentages of the
injected dose per gram (%ID/g).MicroPET/CT imaging
Injections of [18F]FPyPEGCBT-c(RGDfK) to anesthetised mice were conducted as de-
scribed above. Mice were injected intraperitoneally with 700 μL of 132 mg/mL meglumine
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inal organs discrimination and subjected to CT scans in a Triumph microPET/SPECT/CT
system (Trifoil, Chatsworth, CA, USA). Images were obtained at 80 kVp, 160 μA, and
1024 projections were acquired during the 360° rotation with a field of view of 71.3 mm
(1.7× magnification). After 20 min of uptake, PET scans were started for a total duration
of 110 min allowing the reconstructions of PET frames of 30 ± 10 min, 60 ± 10 min and
120 ± 10 min of uptake. PET scans were reconstructed with the LabPET software using an
OSEM3D (20 iterations) algorithm and images were calibrated in Bq/mL by scanning a
phantom cylinder. The Triumph XO software, which uses a back-projection engine, was
used to reconstruct the CT scans with a reconstruction matrix of 512 and a voxel size of
0.135 mm. Reconstructed CTs were then co-registered with the PET scans using the
plugin Vivid (Trifoil) for Amira (FEI, Hillsboro, OR, USA) and exported as dicom files for
mice anatomy visualisation. The software Osirix (Pixmeo, Geneva, Switzerland) was used
to quantitatively analyse the datasets and generate pictures. PET series were converted to
display Standardised Uptake Values (SUV) adjusted to the body weight of the animals
and merged with CT sets. Regions of interest (ROI) were drawn on contiguous slides
according to CT scans. ROIs were subsequently computed to 3D volumes allowing
the quantification of the [18F]FPyPEGCBT-c(RGDfK) uptake in the different organs.Metabolic assay
Fractions of blood collected during biodistribution studies were used to assess metabolic
stability of [18F]FPyPEGCBT-c(RGDfK). Metabolic activity was quenched (v/v) with a
solution of 20 % MeCN in PBS (100 mM, pH 7.4). Blood samples were centrifuged at 4 °C
(2000 × g, 8 min) and the serum was removed. Serum proteins were precipitated with
MeCN (1:1) and centrifuged at 4 °C again (21380 × g, 8 min). Supernatants were removed
from pellets, and the activity associated with both was measured. In this fashion, the
extraction efficiency of this step was estimated to be 91.0 % ± 4.8 (n = 18). For each
sample, an aliquot of supernatant (2 μL) was spotted onto silica gel plates and eluted with
4:6 MeOH-10 % (w/w) aqueous ammonium acetate. Phosphor imaging screens were
exposed to dried TLC plates for 10–25 min and analysed by autoradiography using a
Cyclone plus and the built-in Optiquant software (Perkin Elmer).Figures and statistics
Statistical analyses and regressions were conducted using Graphpad prism. Differences
between samples were assessed using one-way ANOVA statistical test. Figures were
generated using Microsoft Excel, Graphpad Prism, Adobe Photoshop and Adobe
Illustrator.Results
Radiochemistry
The 18F peptide tracer FPyPEGCBT-c(RGDfK) (276–641 MBq) was prepared in yields
of 7 % ± 1 (n = 9) from end-of-bombardment over 124–132 min. Radiochemical purity,
determined by HPLC, was above 95 % and the specific activity was estimated to be
4–12 GBq μmol−1.
Fig. 2 Displacement of [125I]echistatin by FPyPEGCBT-c(RGDfK). U-87 MG and SKOV-3 cancer cells were
co-incubated for 1 h in 96-well plates with 370 Bq/well [125I]echistatin and a concentration range (10−9
to 10−4 M) of FPyPEGCBT-c(RGDfK) or c(RGDfV). After lysis, the cell-associated radioactivity was measured
in a γ-counter. Means ± SD of three independent experiments conducted in quadruplicate well were
fitted by nonlinear regression using GraphPad Prism and R2 fitting correlation coefficients are shown (a).
IC50 values ± SD are also shown (b)
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The binding affinity of FPyPEGCBT-c(RGDfK) was evaluated using a standard in vitro
binding assay on U-87 MG and SKOV-3 cancer cells expressing αVβ3, αVβ5 and α5β1
integrins and compared to a reference peptide c(RGDfV) (Fig. 2). FPyPEGCBT-c(RGDfK)
inhibited the binding of [125I]echistatin in both models in a dose-dependent manner. The
IC50 values of FPyPEGCBT-c(RGDfK) were 30.84 ± 0.02 and 12.50 ± 0.02 × 10
−7 M in
U-87 MG and SKOV-3 models respectively, as compared to 6.00 ± 0.02 and 2.59 ±
0.02 × 10−7 M for c(RGDfV). IC50 values of FPyPEGCBT-c(RGDfK) are only five times
higher than those of the control peptide in both cell lines. It is confirming that the
substitution on the lysine residue has little effect on the binding affinity of cyclic
RGD peptides.Cell uptake of [18F]FPyPEGCBT-c(RGDfK)
Incubation of U-87 MG or SKOV-3 cells with [18F]FPyPEGCBT-c(RGDfK) showed that
this tracer was taken up in a time-dependent manner at a physiological temperature of
37 °C (Fig. 3). The influx of the peptide was inhibited by five to six fold when incubation
was performed at 4 °C for 60 min. This difference demonstrated that [18F]FPyPEGCBT-
c(RGDfK) was primarily taken up by active transporters (Fig. 3a). Co-treatment with an
excess of c(RGDfV) blocked by five to six times the accumulation of [18F]FPyPEGCBT-
c(RGDfK) in cells, to a level corresponding to its passive diffusion (as measured at 4 °C).
Overall, our data confirm that the cellular uptake of this peptide is effectively mediated by
RGD-recognising integrins (Fig. 3b).
Fig. 3 Uptake of [18F]FPyPEGCBT-c(RGDfK) in cancer cells. U-87 MG and SKOV-3 cells were incubated with
100 kBq/mL [18F]FPyPEGCBT-c(RGDfK) for 15 to 120 min at 37 or 4 °C (a). Cells were also co-treated with
10−4 M c(RGDfV) for 1 h (b). Uptake of [18F]FPyPEGCBT-c(RGDfK) was also evaluated after 1 h of incubation
with cells with selective siRNA-mediated knocked down of αV, β1, β3 or β5 integrin subunits and indicated
combinations (c). Depletions were verified by immunoblotting using specific antibodies as compared to
untransfected cells (Unt) and to an irrelevant depletion of luciferase (si Luc). After incubation, cells were
lysed and the cell-associated radioactivity was measured in a γ-counter. Data are means ± SD of at least
three independent experiments performed in quadruplicate well. Statistical differences were analysed
with the one-way ANOVA test followed by Dunnett’s post hoc test as compared to 37 °C controls (b)
or to si Luc (c); #p < 0.001
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was assessed by selective knock down of αV, β1, β3 or β5 in cell uptake assays (Fig. 3c).
The siRNA-mediated depletions of each protein in U-87 MG and SKOV-3 cells were
highly reproducible and no significant interference or feedback on the expression of
non-targeted integrins was observable (Additional file 1: Figure S1). Densitometry
analyses showed that the efficacies of knock down were good in U-87 MG (between
66 and 98 %) and even better in SKOV-3 cells (between 75 and 97 %). Validity of
these depletion models was further confirmed by testing their functionality in
[125I]echistatin uptake assays. These showed that lowering αV, β1, β3 or β5 expressions
highly affected the echistatin uptake (Additional file 1: Figure S2). [18F]FPyPEGCBT-
c(RGDfK) uptake studies in integrin subunit depleted cells demonstrated that αV, β3
and β5 are highly involved in the influx of this radio-peptide since their knock down
strongly interfered with [18F]FPyPEGCBT-c(RGDfK) accumulation in both cell lines
(Fig. 3c). However, depletion of subunit β1 did not interfere with the tracer uptake.Ex vivo biodistribution in tumour-bearing mice
The biodistribution profile of [18F]FPyPEGCBT-c(RGDfK) was assessed in mice bearing
subcutaneous U-87 MG glioblastoma or SKOV-3 ovarian human tumours (Table 1,
Fig. 4a, c, and Additional file 1: Table S1). The uptake of the labelled peptide decreased
over time in both models with %ID/g ranging from 3.6 ± 0.8 to 2.8 ± 0.7 in U-87 MG
and 3.5 ± 0.9 to 2.1 ± 0.6 in SKOV-3 tumours. Retention of the tracer in the blood
remained high (3.8 ± 1.1 %ID/g after 1 h) leading to tumour-to-blood ratios which were
not optimal (0.8 ± 0.1 for U-87 MG and 0.6 ± 0.2 for SKOV-3 at 60 min post injection).
The in vivo stability study showed that blood contained only intact peptide tracer at all
Table 1 Biodistribution data of [18F]FPyPEGCBT-c(RGDfK) in nude mice bearing U-87 MG or
SKOV-3 subcutaneous tumoursa
Organ 30 min 60 min 60 min blocking 120 min
Blood 8.08 ± 1.72 3.76 ± 1.08 6.14 ± 1.39 2.96 ± 1.83
Muscle 1.32 ± 0.32 0.64 ± 0.14 1.12 ± 0.38 0.77 ± 0.16
Bone 1.34 ± 0.34 0.88 ± 0.25 0.91 ± 0.35 1.02 ± 0.30
Heart 3.92 ± 0.78 2.01 ± 0.43 2.99 ± 0.82 1.45 ± 0.45
Lung 6.10 ± 1.39 2.77 ± 0.55 4.83 ± 0.82 2.93 ± 0.82
Pancreas 1.29 ± 0.40 0.71 ± 0.13 1.09 ± 0.39 0.63 ± 0.12
Spleen 1.87 ± 0.25 0.96 ± 0.21 1.28 ± 0.46 1.03 ± 0.34
Adrenals 5.37 ± 0.94 3.47 ± 0.53 1.13 ± 0.51 2.71 ± 0.29
Kidney 6.56 ± 0.85 3.61 ± 0.49 5.59 ± 1.17 2.77 ± 0.77
Liver 8.82 ± 1.25 4.43 ± 1.31 5.19 ± 1.19 5.04 ± 2.07
Stomach 1.48 ± 1.00 1.26 ± 0.58 1.45 ± 1.21 0.60 ± 0.24
Duodenum 30.31 ± 8.17 16.56 ± 8.68 22.38 ± 10.82 31.39 ± 22.29
Jejunum 55.07 ± 47.42 69.80 ± 20.76 45.88 ± 9.85 9.58 ± 7.36
Ileum 2.78 ± 1.23 13.31 ± 7.14 8.45 ± 10.81 8.89 ± 8.33
U-87 MG Tumour 3.56 ± 0.78 2.89 ± 0.53 0.89 ± 0.31 2.80 ± 0.70
SKOV-3 Tumour 3.47 ± 0.93 2.42 ± 0.40 0.73 ± 0.30 2.12 ± 0.56
Tumour-to-non-tumour ratios
U87-MG to Blood 0.44 ± 0.13 0.77 ± 0.06 0.14 ± 0.04 0.83 ± 0.78
U87-MG to Muscle 2.45 ± 0.53 4.51 ± 0.58 0.90 ± 0.30 3.64 ± 1.55
SKOV-3 to Blood 0.43 ± 0.17 0.64 ± 0.18 0.12 ± 0.06 0.63 ± 0.51
SKOV-3 to Muscle 2.39 ± 1.22 3.78 ± 1.08 0.74 ± 0.45 2.76 ± 0.89
aResults are expressed as mean %ID/g at indicated uptake times ± SD (n ≥ 7)
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for U-87 MG and 3.8 ± 1.1 for SKOV-3 were observed at 1 h post injection (Fig. 4c).
In addition, the uptake in many non-targeted organs significantly decreased over time,
which is favourable for a good visualisation of the tumours (see Additional file 1:
Table S1 for statistical analyses). Organs implicated in the excretory pathways
accumulated the peptide tracer as expected, and the %ID/g in the kidneys and liver
decreased in a time-dependent manner. Nevertheless, the uptake in the intestine
remained high over the time and highlighted the importance of the hepatobiliary
pathway in the clearance of [18F]FPyPEGCBT-c(RGDfK). Co-injection of c(RGDfV)
significantly blocked by three to four times the tumour uptake of [18F]FPyPEGCBT-
c(RGDfK) (from 2.9 to 0.9 %ID/g in U-87 MG and 2.4 to 0.7 in SKOV-3) showing the
specificity of its uptake (Table 1, Fig. 4b, d, and Additional file 1: Table S1). No significant
differences were found in other organs, except the adrenals, which are known to express
moderate levels of RGD-recognising integrins.MicroPET imaging
Micro-PET/CT analyses were performed on the same models as the ex vivo biodis-
tribution. Mean SUVs and tumours-to-muscle SUV ratios were calculated after 30,
60 and 120 min (Fig. 5 and Additional file 1: Figure S3). U-87 MG and SKOV-3
tumours were evident 30 min after injection and the related SUVs decreased over
Fig. 4 Biodistribution of [18F]FPyPEGCBT-c(RGDfK) in nude mice bearing U-87 MG or SKOV-3 subcutaneous
tumours. Mice intravenously injected with 3–5 MBq [18F]FPyPEGCBT-c(RGDfK) were sacrificed and indicated
organs were collected after uptake times of 30, 60 or 120 min (a). For the blocking experiments, mice were
injected intravenously with 20 mg/kg of c(RGDfV) 5 min prior to [18F]FPyPEGCBT-c(RGDfK) injection and
indicated organs were collected after 60 min of uptake (b). [18F]FPyPEGCBT-c(RGDfK) uptake in the indicated
organs was quantified in a γ-counter and expressed as percentages of the injected dose per gram (%ID/g)
(a, b). Tumours-to-blood and Tumours-to-muscle %ID/g ratios were also determined for the uptake time
course of [18F]FPyPEGCBT-c(RGDfK) (c) and the blocked experiment (d). Data are means ± SD (n≥ 7) and
statistical differences were analysed with the one-way ANOVA test followed by Dunnett’s post hoc
test as compared with 0.5 h uptake time (c) or with non-blocked 1 h uptake time (d); *p < 0.05,
**p < 0.01, #p < 0.001
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different during the time course. Nevertheless, an obvious overall reduction of the
accumulation of [18F]FPyPEGCBT-c(RGDfK) in non-targeted organs was more favourable
for tumour visualisation at the 60 min timepoint. High tracer accumulation in organs
responsible for the hepatobiliary excretion could be visualized, confirming the ex vivo
biodistribution data. A blocking experiment with c(RGDfV) showed the specificity of the
tracer uptake in U-87 MG and SKOV-3 tumours. Both SUVs and tumour-to-muscle
ratios were diminished by a factor of 3, which is in accordance with the ex vivo biodistri-
bution data.
Discussion
The identification of non-invasive imaging tracers that can specifically target and
quantify proteins controlling cancer progression is crucial for the development of
personalised treatment. RGD-recognising integrins are promising targets, yet few
radioligands targeting integrin receptors have been evaluated clinically to image
angiogenesis and predict response to antiangiogenic therapy. We have recently synthe-
sized a new RGD peptide, dubbed [18F]FPyPEGCBT-c(RGDfK), for the visualization of
Fig. 5 MicroPET/CT images of [18F]FPyPEGCBT-c(RGDfK) in nude mice bearing subcutaneous tumours. Coronal
sections of representative microPET/CT images of nude mice bearing subcutaneous U-87 MG (a, left) and SKOV-3
(a, right) tumours after an uptake time of [18F]FPyPEGCBT-c(RGDfK) of 60 ± 10 min. Tumours are outlined by dashed
circles. Similar experiments were performed with injections of a blocking c(RGDfV) peptide 5 min prior to the tracer
(b). c Mean SUV of [18F]FPyPEGCBT-c(RGDfK) in U-87 MG and SKOV-3 tumours at indicated times (top graph) as
well as in the 60 min-blocked experiment (bottom graph). d Tumours-to-blood and Tumours-to-muscle SUV
ratios were also determined for the uptake time course of [18F]FPyPEGCBT-c(RGDfK) (top graph) and the blocked
experiment (bottom graph). Data are means ± SD (n≥ 5). Statistical differences were analysed with the one-way
ANOVA test followed by Dunnett’s post hoc test as compared with 0.5 h uptake time (c, d, top graphs) or with
non-blocked 1 h uptake time (c, d, bottom graphs); *p< 0.05, #p< 0.001
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18F-labelled cyanobenzothiazole (CBT) prosthetic group with a modified c(RGDfK)
peptide (Inkster et al. 2015). The radiosynthesis relied on the high incorporation of
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2008; Inkster et al. 2009) and the chemoselective ligation of CBT and 1,2-aminothiol
moiety (Jeon et al. 2012). The prosthetic group and the peptide were both functionalized
by a short polyethylene glycol chain to increase the hydrophilicity and bioavailability of
the peptide tracer (Harris and Chess 2003; Wu et al. 2007a). The radiosynthesis of
[18F]FPyPEGCBT-c(RGDfK) was achieved in 130 min, completely automated and required
only one HPLC purification step, which was more practical than [18F]Galacto-c(RGDfK)
(Haubner et al. 2004) but comparable to FPPRGD2 tracer (Liu et al. 2010). In this study
we evaluated the preclinical biological properties of a [18F]FPyPEGCBT-c(RGDfK)
in vitro, as well as in vivo, in a glioblastoma (U-87 MG) and an ovarian (SKOV-3)
cancer model.
The binding properties of FPyPEGCBT-c(RGDfK) as assessed in a cell-binding assay
demonstrated favourable albeit slightly lower IC50 values when compared to the
reference c(RGDfV) peptide. A reduction of binding affinity upon insertion of a PEG
modification has been previously reported (Chen et al. 2004a; Chen et al. 2004b). The
binding properties of FPyPEGCBT-c(RGDfK) were in the same range than other
potent monomeric c(RGD) derivatives like Galacto-c(RGDfK) (Liu et al. 2010). An
increase of binding affinity of c(RGD) peptides is usually observed with a higher
degree of multimerisation (Li et al. 2007). Indeed, IC50 measurements of the c(RGD)
tetramer FPRGD4 (3.8 × 10−8 M) and the dimer FPPRGD2 (5.2 × 10−8 M) are an order
of magnitude lower than the IC50 values of monomers like Galacto-c(RGDfK)
(4.0 × 10−7 M) or FPyPEGCBT-c(RGDfK) (30.84 × 10−7 M) (Liu et al. 2010; Wu
et al. 2007b). Nevertheless, the higher binding properties of FPRGD4 did not translate
to improved results in vivo because of high background accumulation. Based on
clinical studies with [68Ga]NOTA-c(RGDyK) (Jeong et al. 2008; Kim et al. 2012) and
the dimers [18F]FRGD2 and [18F]FPPRGD2 (Chen et al. 2004a; Zhang et al. 2006; Wu
et al. 2007a; Choyke 2011; Mittra et al. 2011; Liu et al. 2010), it seems that the most
favourable conformations are the monomeric and dimeric scaffolds.
Further in vitro characterization of [18F]FPyPEGCBT-c(RGDfK) showed that 80 to
90 % of its internalisation was mediated by an integrin-related active transport in both
cell lines studied. Furthermore, siRNA depletion experiments demonstrated that αV, β3
and β5 but not β1 subunits were responsible for [
18F]FPyPEGCBT-c(RGDfK) uptake.
Similarly, other c(RGD) peptides have been shown to specifically bind both αVβ3 and
αVβ5 integrins by ELISA (Maschauer et al. 2014). Taken together, these results show
that the αVβ3-specificity claimed for many RGD peptide tracers cannot be concluded
from competitive cell binding assay in the U-87 MG model. Promising peptide ligands
with alternative binding motifs have recently been reported, including a) αVβ3 but not
αVβ5 integrin (Zannetti et al. 2009); b) exclusively α5β1 (Neubauer et al. 2013; Haubner
et al. 2014b); and c) exclusively αVβ6 (Hausner et al. 2009). Such compounds have the
potential to yield highly specific radiotracers.
Distribution of [18F]FPyPEGCBT-c(RGDfK) was assessed in mice bearing subcutaneous
U-87 MG or SKOV-3 tumours by ex vivo analysis of selected tissues and microPET
imaging. The specificity of ligand binding to RGD-recognising integrins was challenged
by pre-injection of an excess of c(RGDfV). This demonstrated a significant reduction of
the tumour uptake whereas no differences were observed in normal tissues except in the
adrenals, which are known to express moderate levels of RGD-recognising integrins. The
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ranged between 3.6 and 2.8 %ID/g over the 30 to 120 min time course; similar results
were obtained in the SKOV-3 model. These uptake values were higher than those
reported for the monomeric peptide tracer [18F]Galacto-c(RGDfK) (≈1.2 %ID/g in U-87
MG), and similar to dimeric c(RGD) tracer [18F]FPPRGD2 (≈2.8 %ID/g), but lower than
[18F]CBTRGD2 (4.25 %ID/g) (Liu et al. 2010; Jeon et al. 2012). Tumour-to-muscles ratios
of [18F]FPyPEGCBT-c(RGDfK) (≈4.0 measured by ex vivo biodistribution and ≈ 3.0 by
PET imaging 1 h after injection) clearly allowed the visualisation of U-87 MG and
SKOV-3 subcutaneous tumours by microPET imaging. These ratios are similar to
[18F]CBTRGD2, but inferior to [18F]Galacto-c(RGDfK) or [18F]FPPRGD2 which exhibit
ratios as high as 10 (Liu et al. 2010; Jeon et al. 2012). The relatively low tumour-to-
background ratio of [18F]FPyPEGCBT-c(RGDfK) could be attributed to its prolonged
presence in the blood, which resulted in its increased bioavailability but also to higher
background accumulation. Moreover, the unwanted retention of convoluting radio-
activity in the liver and the intestines suggests a significant degree of excretion via the
hepatobiliary pathway. High excretion via this pathway rather than the renal route is
widely thought to be correlated with the degree of lipophilicity of pharmaceuticals. It
was anticipated that the inherent lipophilicity of CBT moiety might be counteracted
by the two short PEG chains of [18F]FPyPEGCBT-c(RGDfK) (Jeon et al. 2012). Unfor-
tunately, [18F]FPyPEGCBT-c(RGDfK) exhibits a higher lipophilicity than other potent
c(RGD) peptide tracers (log D value of −1.2 vs. -2.3 to −3.2) (Haubner et al. 2004; Wu
et al. 2007a; Inkster et al. 2015), which could account for its hepatobiliary excretion.
Taken all together, our results suggest that [18F]FPyPEGCBT-c(RGDfK) would require
some design optimization to yield a clinical relevant radiolabeled RGD peptide for
non-invasive angiogenesis imaging. At first, a dimer scaffold should be considered to
increase the affinity towards the RGD-recognising integrin receptors. Then, to improve
the biodistribution profile, the water solubility and lipophilicity have to be better balanced.
It can effectively be achieved by: i) the introduction of a longer polyethylene glycol chain
spacer, or ii) the presence of a positive charge, known to favour renal elimination, or
iii) attachment of a chelating agent and subsequent labelling with a radiometal. Such
structural modifications should lead to a tracer with improved pharmacokinetic/
pharmacodynamics properties, namely a better accumulation of the tracer in the
tumour, higher tumour-to-background ratios, lower uptake in non-target organs, and
a faster clearance from the blood.Conclusion
[18F]FPyPEGCBT-c(RGDfK) demonstrated good specificity towards tumours expressing
RGD-recognising integrins and was suitable for their detection in preclinical models.
Indeed, this peptide tracer which binds to αVβ3 and αVβ5 integrins, showed a high stability
in vivo and its favourable tumour uptake combined with a good tumour-to-background
contrast was comparable to other reported RGD-based tracers. Nevertheless, its hepato-
biliary excretion route could impair its general utility as a cancer-imaging agent. Because
of the [18F]FPyPEGCBT-mediated radiolabeling approach is rapid and fully automated, it
should prove useful for the 18F labelling of other biological targeting vectors which
warrant clinical study, including c(RGDfK) multimers (Choyke 2011).
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Additional file 1: Table S1. Statistical analyses of the biodistribution data of [18F]FPyPEGCBT-c(RGDfK) in nude
mice bearing U-87 MG or SKOV-3 subcutaneous tumoursa. Figure S1. siRNA-mediated integrin depletions analysis
by densitometry. αV, β1, β3 or β5 integrin subunits and indicated combinations were knocked-down by siRNA in
U-87 MG and SKOV-3 and protein extracts were submitted to immunoblotting using specific antibodies. Expression
levels of each integrin were then quantified with a Chemidoc MP. Data are mean fold expression changes in
indicated samples as compared to untransfected cells (Unt) ± SD (n = 3). Figure S2. Uptake of [125I]echistatin in
cells with selective siRNA-mediated integrin knocked down. U-87 MG and SKOV-3 cells knocked down for αV,
β1, β3 or β5 integrin subunits and indicated combinations were incubated with 100 kBq/mL [18F]FPyPEGCBT-
c(RGDfK) for 15 to 120 min at 37 °C. Depletions were verified by immunoblotting using specific antibodies as
compared to untransfected cells (Unt) and to an irrelevant depletion of luciferase (si Luc). After incubation, cells
were lysed and the cell-associated radioactivity was measured in a γ-counter. Data are means ± SD of at least
three independent experiments performed in quadruplicate well. Statistical differences were analysed with
the one-way ANOVA test followed by Dunnett’s post hoc test as compared to si Luc controls; #p < 0.001.
Figure S3. MicroPET/CT images of [18F]FPyPEGCBT-c(RGDfK) in nude mice bearing subcutaneous tumours.
Coronal sections of representative microPET/CT images of nude mice bearing subcutaneous U-87 MG (a)
and SKOV-3 (b) tumours after indicated uptake times of [18F]FPyPEGCBT-c(RGDfK). Tumours are outlined by
dashed circles. Figure S4. a, representative radio-TLC of mouse serum 2 h after injection of [18F]FPyPEGCBT-c(RGDfK).
TLC eluent: 6:4 10 % aqueous ammonium acetate: MeOH. RF = 0.8. b, Radio-TLC of [
18F]FPyPEGCBT-c(RGDfK). TLC eluent:
6:4 10 % aqueous ammonium acetate: MeOH. RF = 0.8. c, Radio-TLC of free [
18F]F-. TLC eluent: 6:4 10 % aqueous
ammonium acetate: MeOH. RF = 0.3. (DOCX 2083 kb)
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